A Study of the Effectiveness & Safety of Topiramate in the Treatment of

Status Completed

Clinical Trial Summary

The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled study to evaluate the effectiveness of two dose levels of topiramate (400 and 600 milligrams/day) compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder. The trial consists of 3 phases: a screening period; double-blind treatment for 12 weeks; and an optional open-label period of at least 6 months. Assessment of effectiveness include change from baseline to Day 21 for the Young Mania Rating Scale (YMRS) total score. Also included during the 12 week study are the Global Assessment Scale (GAS), Montgomery-Åsberg Depression Rating Scale (MADRS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions (CGI), and health-related quality of life measures at specified time intervals. Safety assessments include evaluation of adverse events, rate of withdrawal from the study due to adverse events, and vital signs (blood pressure and pulse) throughout the study, as well as changes in clinical laboratory tests (hematology, biochemistry, urinalysis), electrocardiograms (ECGs), and physical examinations at specified times. The study hypothesis is that the change from baseline in Young Mania Rating Scale (YMSR) total score at Day 21 will be significantly better for the topiramate groups than for the placebo group. Topiramate tablets (50 or 100 milligrams) or placebo, beginning at 50mg daily and increasing over the first week to a maximum of 400mg/day or 600mg/day, depending on study group. Maximum dosage continues up to 12 weeks. Dosage can be decreased or increased at investigator's discretion. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00240721
Study type	Interventional
Source	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact
Status	Completed
Phase	Phase 3
Start date	October 2000
Completion date	September 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Recruiting	`NCT05345392` - Brain, Emotions, and Mind-Wandering	N/A
Completed	`NCT05078450` - Mood Lifters Online for Graduate Students and Young Professionals	N/A
Not yet recruiting	`NCT04551027` - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness	N/A
Recruiting	`NCT03088657` - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Active, not recruiting	`NCT02542475` - Low Field Magnetic Stimulation: Open Label Study.	Phase 1/Phase 2
Completed	`NCT00916552` - Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder	Phase 2
Completed	`NCT00202514` - Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms	Phase 2/Phase 3
Completed	`NCT00217932` - Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings	Phase 2
Completed	`NCT00006517` - Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)	N/A
Terminated	`NCT03898843` - Assisted Animal Therapy: ReAnimal	N/A
Recruiting	`NCT04358900` - Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Recruiting	`NCT06360562` - Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)	N/A
Completed	`NCT05745103` - Optimizing Behavioral Healthcare Delivery Through Technology	N/A
Suspended	`NCT03715400` - Mobile Virtual Positive Experiences for Anhedonia	N/A
Enrolling by invitation	`NCT03736538` - Nitrous Oxide- Suicidal Ideation	Phase 1
Completed	`NCT04601545` - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method	N/A
Completed	`NCT02566980` - Biological Triggers of Depression in Pregnancy
Completed	`NCT03743844` - Psychosocial Intervention for Women With Mood Disorders Seeking Treatment for Obesity	N/A
Completed	`NCT05211063` - Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms